



**Oncode
Accelerator**

*Outsmarting cancer
Impacting lives*

**Accelerating the
development of
cancer therapies**

Developing cancer therapies


The development process of cancer therapies is a high-risk, expensive and time-consuming endeavor, often resulting in new therapies only benefiting a subset of the intended patient population.

Oncode Accelerator aims to change this by revolutionizing the crucial phase of preclinical development.

Bringing patients into the lab


To accelerate the development of safe and effective therapies, Onco Accelerator brings patients into the preclinical development process.

This is achieved through the power of three innovation platforms: Patient Cohorts, Organoids and Artificial Intelligence.




Patient Cohorts

Data from well-defined Patient Cohorts will increase the effectiveness of the preclinical development process. The real-time and real-world nature of the data allows for identification of medical needs, early validation and an increased probability of finding successful therapies for predefined patients groups.



Organoids

Organoid models allow for clinically relevant screening of the safety and efficacy of therapeutic candidates. By building a National Organoid Center we enable the identification of patient populations most likely to benefit from new therapies.



Artificial Intelligence

AI-tools will be trained and implemented throughout the preclinical development process. They will aid to identify and optimize therapeutic candidates, predict the efficacy of therapies and identify potential patients for proof-of-concept studies.



Dynamic collaboration


Oncode Accelerator is a collaboration of more than 30 public and private partners. In parallel, Oncode Accelerator will connect and scale-up existing capacity, integrate Innovation Platforms and run Demonstrator Projects to build a sustainable oncology ecosystem in the Netherlands.

Four types of cancer therapies


Oncode Accelerator sets up preclinical development pipelines for four product types:



Small Molecules



Biologics



**Therapeutic
Vaccines**




**Cell and Gene
Therapy**

Delivering potential therapies ready to enter the clinical phase

To validate the innovated preclinical discovery & development process, Onco Accelerator funds the execution of preclinical discovery-development projects called Demonstrator Projects. These are executed using a Workstream and one or more innovations of the Innovation Platforms. Ultimately, the aim is to deliver novel clinical candidates with a high chance of success in a well-defined patient population.

A transparent and standardized approach

The independent Demonstrator Advisory Board plays a central role in the assessment of Demonstrator Project proposals.



What is in it for you?

Co-funding for discovery and preclinical development of your lead asset.

•

Access to innovative approaches in discovery & preclinical development.

•

Access to well-defined patient cohorts, patient data and patient-derived models.

•

Better prediction of efficacy and safety using AI.

•

Accelerated development of de-risked clinical candidates.

•

Project support throughout the entire process, from intake to finalization of Demonstrator Projects.



Key to success

Key to the success of the Oncode Accelerator program will be the selection of high-quality Demonstrator Projects which aim to validate the innovated Oncode Accelerator infrastructure and demonstrate the accelerated development of novel clinical candidates.

We are welcoming partners to work with us and turn your assets into de-risked clinical candidates. As a partner of our unique cancer research network, you will have access to state-of-the-art equipment, world-class research institutes and industry, top scientists, and a dedicated team to manage the process from start to finish.



Scan the QR code to get started with your Demonstrator Project!

Six Coordinating Partners

The Oncode Accelerator program is steered
by six Coordinating Partners:



**Oncode
Accelerator**
Foundation



**prinses
máxima
centrum**
kinderoncologie



NETHERLANDS
CANCER
INSTITUTE
ANTONI VAN LEEUWENHOEK



UMC Utrecht



Leiden University
Medical Center



**Universiteit
Leiden**

Oncode Accelerator is a public-private partnership with a total budget of approximately €700 million, of which €325 million is funded by the Dutch National Growth Fund (NGF).



Let's accelerate together

OncodeAccelerator.nl

 OncodeAccelerator

 info@oncodeaccelerator.nl

